Induction Therapy in Pediatric Renal Transplant Recipients

Olga Charnaya; Asha Moudgil; Dechu Puliyanda

doi:10.1007/978-981-19-6909-6_9

Induction Therapy in Pediatric Renal Transplant Recipients

Olga Charnaya, Asha Moudgil, Dechu Puliyanda

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Induction therapy to prevent acute rejection of mismatched allografts with the goal of prolonging the life of the allograft has been the cornerstone of immunosuppression since the beginning of renal transplantation. Agents used for induction have changed over time, and their role in transplantation has expanded to enable steroid avoidance and immunosuppression minimization. The choice of induction agent should be determined by an assessment of a patient’s individual immunological risk based on a combination of factors, including underlying kidney disease with possible high risk of recurrence, degree of allosensitization, risk for nonadherence, delayed graft function, and/or prolonged cold ischemic time. Induction in standard-risk and immunologically high-risk patients is discussed in this chapter.

Original language	English (US)
Title of host publication	Pediatric Solid Organ Transplantation
Subtitle of host publication	A Practical Handbook
Publisher	Springer Nature
Pages	109-131
Number of pages	23
ISBN (Electronic)	9789811969096
ISBN (Print)	9789811969089
DOIs	https://doi.org/10.1007/978-981-19-6909-6_9
State	Published - Jan 1 2023

Keywords

Acute rejection
Allosensitization
Induction immunosuppression
Kidney transplant
Lymphocyte depletion

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-981-19-6909-6_9

Cite this

@inbook{ff538470ec774b2b96920708cf9b26eb,

title = "Induction Therapy in Pediatric Renal Transplant Recipients",

abstract = "Induction therapy to prevent acute rejection of mismatched allografts with the goal of prolonging the life of the allograft has been the cornerstone of immunosuppression since the beginning of renal transplantation. Agents used for induction have changed over time, and their role in transplantation has expanded to enable steroid avoidance and immunosuppression minimization. The choice of induction agent should be determined by an assessment of a patient{\textquoteright}s individual immunological risk based on a combination of factors, including underlying kidney disease with possible high risk of recurrence, degree of allosensitization, risk for nonadherence, delayed graft function, and/or prolonged cold ischemic time. Induction in standard-risk and immunologically high-risk patients is discussed in this chapter.",

keywords = "Acute rejection, Allosensitization, Induction immunosuppression, Kidney transplant, Lymphocyte depletion",

author = "Olga Charnaya and Asha Moudgil and Dechu Puliyanda",

note = "Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-981-19-6909-6_9",

language = "English (US)",

isbn = "9789811969089",

pages = "109--131",

booktitle = "Pediatric Solid Organ Transplantation",

publisher = "Springer Nature",

address = "United States",

}

TY - CHAP

T1 - Induction Therapy in Pediatric Renal Transplant Recipients

AU - Charnaya, Olga

AU - Moudgil, Asha

AU - Puliyanda, Dechu

N1 - Publisher Copyright: © Springer Nature Singapore Pte Ltd. 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Induction therapy to prevent acute rejection of mismatched allografts with the goal of prolonging the life of the allograft has been the cornerstone of immunosuppression since the beginning of renal transplantation. Agents used for induction have changed over time, and their role in transplantation has expanded to enable steroid avoidance and immunosuppression minimization. The choice of induction agent should be determined by an assessment of a patient’s individual immunological risk based on a combination of factors, including underlying kidney disease with possible high risk of recurrence, degree of allosensitization, risk for nonadherence, delayed graft function, and/or prolonged cold ischemic time. Induction in standard-risk and immunologically high-risk patients is discussed in this chapter.

AB - Induction therapy to prevent acute rejection of mismatched allografts with the goal of prolonging the life of the allograft has been the cornerstone of immunosuppression since the beginning of renal transplantation. Agents used for induction have changed over time, and their role in transplantation has expanded to enable steroid avoidance and immunosuppression minimization. The choice of induction agent should be determined by an assessment of a patient’s individual immunological risk based on a combination of factors, including underlying kidney disease with possible high risk of recurrence, degree of allosensitization, risk for nonadherence, delayed graft function, and/or prolonged cold ischemic time. Induction in standard-risk and immunologically high-risk patients is discussed in this chapter.

KW - Acute rejection

KW - Allosensitization

KW - Induction immunosuppression

KW - Kidney transplant

KW - Lymphocyte depletion

UR - http://www.scopus.com/inward/record.url?scp=85171504270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171504270&partnerID=8YFLogxK

U2 - 10.1007/978-981-19-6909-6_9

DO - 10.1007/978-981-19-6909-6_9

M3 - Chapter

AN - SCOPUS:85171504270

SN - 9789811969089

SP - 109

EP - 131

BT - Pediatric Solid Organ Transplantation

PB - Springer Nature

ER -

Induction Therapy in Pediatric Renal Transplant Recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this